NAUT - NASDAQ

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%

HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$327.86M

EPS-0.4700

P/E Ratio-5.49

Earnings Date08/04/2026

191.11M

Assets

-21%

3Y-45.0%

5Y+125.0%

10Y+31.0%

34.14M

Total Liabilities

3Y-3.0%

5Y-70.0%

10Y-76.0%

156.97M

Total Equity

-25%

3Y-50.0%

5Y-628.0%

10Y+3039.0%

Nautilus Biotechnology, Inc. Funding & Solvency Profile

NAUT · NASDAQ

Current Assets

Cash & Cash Equivalents12.39M

Net Receivables0.00

Inventory0.00

Other Current Assets2.56M

Total Current Assets106 M

Non-Current Assets

Property, Plant & Equipment31.23M

Goodwill & Intangible Assets0.00

Long-Term Investments52.74M

Other Non-Current Assets1.18M

Total Non-Current Assets85 M

Total Assets

191.11M

Financial Health Analysis

Current Ratio

13.33x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.22x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

98 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

55% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Nautilus Biotechnology, Inc. Balance Sheet

NAUT • NASDAQ

Nautilus Biotechnology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	12.4M	27.6M	19.4M	114.5M	185.6M	36.6M	595K	1.2M
Short-Term Investments	91M	102.2M	154M	69.9M	160.1M	40.1M	16.1M	144.5B
Cash & Short-Term Investments	103.4M	129.9M	173.4M	184.5M	345.7M	76.7M	16.7M	144.5B
Prepaids	0.0	0.0	0.0	2.7M	3.5M	917K	305K	0.0
Other Current Assets	2.6M	2.9M	3.4M	0.0	0.0	0.0	0.0	-144.5B
Total Current Assets	106M	132.8M	176.8M	187.2M	349.2M	77.7M	17M	1.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	31.2M	32.3M	36.9M	32.6M	31.9M	6.2M	1.1M	0.0
Long-Term Investments	52.7M	76.4M	90.6M	129.2M	16.4M	0.0	0.0	144.5M
Other Non-Current Assets	1.2M	1.2M	1.2M	1.1M	997K	1.1M	459K	0.0
Total Non-Current Assets	85.1M	109.9M	128.7M	162.8M	49.2M	7.4M	1.6M	144.5M
Total Assets	191.1M	242.7M	305.6M	350.1M	398.5M	85M	18.5M	145.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	943K	987K	1.6M	1.3M	1.7M	470K	289K	0.0
Accounts Payable	943K	987K	1.6M	1.3M	1.7M	470K	289K	0.0
Accrued Expenses	0.0	0.0	976K	3.1M	2.7M	452K	124K	0.0
Short Term Debt	3.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	4.1M	3.5M	2M	970K	1.5M	0.0	0.0
Other Current Liabilities	3.2M	2.5M	3M	438K	388K	617K	77K	5K
Total Current Liabilities	8M	7.6M	9.1M	6.8M	5.8M	3M	490K	5K
NON-CURRENT LIABILITIES
Long Term Debt	26.2M	0.0	0.0	0.0	0.0	0.0	275M	5M
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	108.4M	0.0	0.0
Total Non-Current Liabilities	26.2M	26.4M	31.1M	28.3M	29.1M	111.7M	275M	5M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	-275M	135.8M
Capital Lease Obligations	0.0	30.5M	34.6M	30.3M	30M	4.8M	0.0	0.0
Total Liabilities	34.1M	34M	40.2M	35.1M	34.9M	114.7M	490K	140.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	32.6M	0.0
Common Stock	13K	13K	13K	12K	12K	1K	1K	0.0
Additional Paid-In Capital	0.0	481.7M	467.8M	455.3M	444.4M	600K	189K	0.0
Retained Earnings	-332M	-273M	-202.2M	-138.6M	-80.6M	-30.3M	-14.7M	626.6K
Accumulated Other Comprehensive Income/Loss	243K	57K	-255K	-1.9M	-184K	3K	7K	0.0
Other Total Stockholders' Equity	488.7M	0.0	0.0	0.0	0.0	0.0	0.0	4.4M
Total Stockholders' Equity	157M	208.7M	265.4M	314.9M	363.6M	-29.7M	18.1M	5M
Total Equity	157M	208.7M	265.4M	314.9M	363.6M	-29.7M	18.1M	5M
SUMMARY
Total Liabilities & Equity	191.1M	242.7M	305.6M	350.1M	398.5M	85M	18.5M	145.8M
Total Investments	143.8M	178.7M	244.7M	199.1M	176.5M	40.1M	16.1M	144.6B
Total Debt	30M	30.5M	34.6M	30.3M	30M	4.8M	275M	5M
Net Debt	17.6M	2.8M	15.2M	-84.2M	-155.6M	-31.8M	274.4M	3.8M
Shares Outstanding	126,305,122	126,305,122	126,305,122	126,305,122	126,305,122	126,305,122	126,305,122	126,305,122

SEC Filings

NAUT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 17, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 28, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 03, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 28, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 28, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	July 31, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 31, 2025	July 31, 2025	2025	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your NAUT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.